Neonc Technologies (NASDAQ:NTHI) Stock Rating Cut to Strong Sell at Zacks Research

Posted by Francis Steltz on Oct 9th, 2026

Zacks Research lowered shares of Neonc Technologies (NASDAQ:NTHI – Free Report) from a hold rating to a strong sell rating in a report released on Wednesday,Zacks reports.

Other equities research analysts have also issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $15.00 price objective on shares of Neonc Technologies in a report on Tuesday, September 8th. Roth Capital assumed coverage on shares of Neonc Technologies in a research report on Thursday, September 24th. They set a “buy” rating for the company. Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Neonc Technologies has a consensus rating of “Hold” and a consensus price target of $16.00.

Read Our Latest Report on Neonc Technologies

Neonc Technologies Price Performance

Shares of NASDAQ NTHI opened at $2.53 on Wednesday. The stock has a fifty day simple moving average of $3.84 and a two-hundred day simple moving average of $4.55. Neonc Technologies has a 1-year low of $2.52 and a 1-year high of $12.10.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Insider Buying and Selling at Neonc Technologies

In other Neonc Technologies news, CEO Thomas C. Chen acquired 12,757 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were acquired at an average price of $5.49 per share, for a total transaction of $70,035.93. Following the completion of the acquisition, the chief executive officer owned 13,705 shares in the company, valued at $75,240.45. This trade represents a 1,345.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amir F. Heshmatpour bought 35,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were acquired at an average price of $3.30 per share, with a total value of $115,500.00. Following the completion of the acquisition, the chief executive officer directly owned 3,183,000 shares of the company’s stock, valued at approximately $10,503,900. The trade was a 1.11% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 134,812 shares of company stock worth $530,149.

Institutional Investors Weigh In On Neonc Technologies

Several hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new position in shares of Neonc Technologies in the 2nd quarter worth about $1,017,000. BlackRock Inc. bought a new position in shares of Neonc Technologies in the second quarter worth approximately $815,000. Global Retirement Partners LLC purchased a new stake in shares of Neonc Technologies during the second quarter valued at approximately $126,000. Finally, Westmount Partners LLC increased its position in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares in the last quarter.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.